TY - JOUR
T1 - Antitumor activity of a hydrogel loaded with lipophilic bismuth nanoparticles on cervical, prostate, and colon human cancer cells
AU - Cabral-Romero, Claudio
AU - Solís-Soto, Juan M.
AU - Sánchez-Pérez, Yesennia
AU - Pineda-Aguilar, Nayely
AU - Meester, Irene
AU - Pérez-Carrillo, Esther
AU - Nakagoshi-Cepeda, Sergio E.
AU - Sánchez-Nájera, Rosa I.
AU - Nakagoshi-Cepeda, María A.A.
AU - Hernandez-Delgadillo, Rene
AU - Chellam, Shankararaman
AU - García-Cuéllar, Claudia M.
N1 - Publisher Copyright:
© 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - The objective of this study was to analyze the antitumor activity of a hydrogel loaded with lipophilic bismuth nanoparticles on human cervical, prostate, and colon cancer cell lines. The effect of lipophilic bismuth nanoparticles on the viability of cancer cell lines (HeLa, DU145, and HCT-116) and non-cancer lung fibroblasts (HLF; LL 47[MaDo]) was determined with the MTT cell viability assay and compared with known antineoplastic drugs. The biocompatibility at an organismal level was verified in a murine model by histological examination. A lipophilic bismuth nanoparticle hydrogel at 50 µM time-dependently inhibited the growth of the three cancer cell lines, in a time-dependent way. A 1-hour exposure to 250 µM lipophilic bismuth nanoparticle hydrogel, inhibited the growth of the three cancer cell lines. The in-vitro efficacy of lipophilic bismuth nanoparticle was similar to the one of docetaxel and cisplatin, but without inhibiting the growth of non-cancer control cells. Histology confirmed the biocompatibility of lipophilic bismuth nanoparticles as there were no signs of cytotoxicity or tissue damage in any of the evaluated organs (kidney, liver, brain, cerebellum, heart, and jejunum). In conclusion, a lipophilic bismuth nanoparticle hydrogel is an innovative, low-cost alternative for the topical treatment of cervicouterine, prostate, and colon human cancers.
AB - The objective of this study was to analyze the antitumor activity of a hydrogel loaded with lipophilic bismuth nanoparticles on human cervical, prostate, and colon cancer cell lines. The effect of lipophilic bismuth nanoparticles on the viability of cancer cell lines (HeLa, DU145, and HCT-116) and non-cancer lung fibroblasts (HLF; LL 47[MaDo]) was determined with the MTT cell viability assay and compared with known antineoplastic drugs. The biocompatibility at an organismal level was verified in a murine model by histological examination. A lipophilic bismuth nanoparticle hydrogel at 50 µM time-dependently inhibited the growth of the three cancer cell lines, in a time-dependent way. A 1-hour exposure to 250 µM lipophilic bismuth nanoparticle hydrogel, inhibited the growth of the three cancer cell lines. The in-vitro efficacy of lipophilic bismuth nanoparticle was similar to the one of docetaxel and cisplatin, but without inhibiting the growth of non-cancer control cells. Histology confirmed the biocompatibility of lipophilic bismuth nanoparticles as there were no signs of cytotoxicity or tissue damage in any of the evaluated organs (kidney, liver, brain, cerebellum, heart, and jejunum). In conclusion, a lipophilic bismuth nanoparticle hydrogel is an innovative, low-cost alternative for the topical treatment of cervicouterine, prostate, and colon human cancers.
UR - http://www.scopus.com/inward/record.url?scp=85079341586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079341586&partnerID=8YFLogxK
U2 - 10.1097/CAD.0000000000000863
DO - 10.1097/CAD.0000000000000863
M3 - Article
C2 - 31764012
SN - 0959-4973
VL - 31
SP - 251
EP - 259
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 3
ER -